Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive to BCG Therapy
interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC
Non Muscle Invasive Bladder Cancer
DRUG: intravesical Chemotherapy docetaxel/gemcitabine
eficacy, Complete Response rate, 3 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, To evaluate safety and tolerability of systemic pembrolizumab in combination with intravesical gemcitabine/docetaxel, 1 year
patients will receive intrravesical chemotherapy every 3 weeks and systemic pembrolizumb every 6 week. for a total of 1 year of treatment